10-Q: Scorpius Holdings Ceases Operations, Sells Assets Amid Defaults

Scorpius Holdings, Inc. has ceased all operations, sold its primary assets, and faces substantial doubt about its ability to continue as a going concern after defaulting on significant debt.

Summary

• Scorpius Holdings, Inc. has ceased all operations and is now considered a "Shell Company" following the sale of its CDMO biomanufacturing facility assets.
• The company sold substantially all its pledged assets on December 10, 2025, for $16,253,147, with net proceeds of $15,219,552 applied against debt.
• The principal manufacturing lease was terminated on March 24, 2025, due to non-payment of rent, resulting in a $4,132,767 loss.
• The company defaulted on December 2024 Secured Convertible Notes and 2025 Non-Convertible Promissory Notes, with total outstanding debt of $14,460,205 and $485,888 respectively as of January 12, 2026, after asset sale proceeds.
• Revenue for the six months ended June 30, 2025, decreased significantly to $439,798 from $4,273,892 in the prior year period.
• Net loss for the six months ended June 30, 2025, increased to $15.6 million from $13.9 million in the prior year period.
• Cash and cash equivalents stood at $0.5 million as of June 30, 2025, but were less than $0.1 million as of January 12, 2026, with funds anticipated to last only through January 2026.
• The company was delisted from the NYSE American on May 1, 2025, and now trades on the OTC Markets Pink Limited exchange.
• Management has identified substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 1

Explanation: The company has ceased all operations, sold its primary assets, defaulted on significant debt, been delisted, and faces imminent bankruptcy or liquidation without a successful strategic alternative or capital raise, which is highly uncertain.

Negatives

• Cessation of all operations and status as a "Shell Company."
• Revenue for the three months ended June 30, 2025, decreased by $0.53 million (70%) to $0.2 million compared to $0.76 million in the prior year.
• Revenue for the six months ended June 30, 2025, decreased by $3.83 million (89.7%) to $0.44 million compared to $4.27 million in the prior year.
• Net loss for the six months ended June 30, 2025, increased to $15.6 million from $13.9 million in the prior year.
• Accumulated deficit grew to $302.0 million as of June 30, 2025.
• Cash and cash equivalents were $0.5 million as of June 30, 2025, and less than $0.1 million as of January 12, 2026, with funds anticipated to last only through January 2026.
• Default on December 2024 Secured Convertible Notes ($19,376,084 due) and 2025 Non-Convertible Promissory Notes ($10,789,561 due) as of September 9, 2025.
• Delisting from NYSE American on May 1, 2025, due to non-compliance with filing standards and low stock price.
• Termination of the principal manufacturing lease on March 24, 2025, due to non-payment of rent, resulting in a $4,132,767 loss.
• Material weaknesses in internal control over financial reporting persist.
• Loss on settlement of related party receivable of $0.8 million for the six months ended June 30, 2025.
• Loss on lease assignment and termination of $5.7 million for the six months ended June 30, 2025.
• Loss on disposal of long-lived assets of $0.7 million for the six months ended June 30, 2025.

Risks

• Inability to generate revenue in the near future due to cessation of CDMO operations and asset sale.
• Substantial doubt about the ability to continue as a going concern, with current cash sufficient only through January 2026.
• Failure to raise additional capital through strategic transactions (reverse merger, asset acquisition) or financing, potentially leading to bankruptcy or liquidation.
• Negative impact of "Shell Company" status on attracting investors and removing restricted stock legends.
• Dilution of existing stockholders' ownership if additional equity financing is pursued.
• Restrictive covenants in debt agreements impacting business operations and ability to incur new indebtedness.
• Inability to utilize a Form S-3 registration statement for capital raises until relisted on a national exchange or public float exceeds $75 million.
• Limitations on capital raises in certain states due to blue sky laws and inability to raise capital through certain financings until SEC filings are current.
• Material weaknesses in internal control over financial reporting, potentially leading to inaccurate financial statements or failure to meet reporting obligations.
• Dependence on loans from a senior lender who has no obligation to continue funding.

Future Outlook

The company has ceased all operations and does not anticipate generating any revenue in the near term. It expects to generate revenue only if it consummates a strategic transaction, such as a reverse merger or asset acquisition, but there is no assurance of finding a suitable candidate or funding. Current cash is expected to fund public company expenses only through January 2026, and without additional capital or a strategic alternative, the company may need to file for bankruptcy, liquidate, or reorganize.

Management Comments

• "We do not anticipate generating any revenue from operations in the near term."
• "We do not expect to generate revenue unless and until we consummate a strategic transaction such as a reverse merger or asset acquisition."
• "However, we can provide no assurance that we will be able to find a merger candidate or funding to acquire other assets."
• "If are unable to find financing or undertake a strategic alternative we may need to file for bankruptcy, liquidate our company or reorganize the Company, or a combination of the foregoing."
• "Our current cash is anticipated to be sufficient to fund our ongoing public company expenses only through January 2026."
• "Management has determined that there is substantial doubt about our ability to continue as a going concern within one year after the consolidated financial statements are issued."

Industry Context

The company's cessation of CDMO biomanufacturing operations and subsequent status as a "Shell Company" removes it from direct participation in the contract development and manufacturing organization (CDMO) industry. Its future is now entirely dependent on a successful strategic transaction, such as a reverse merger or asset acquisition, rather than organic growth within a specific industry.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• Restated Elusys Convertible Note, Related Party, issued to Elusys Holdings, Inc., a company controlled by CEO Jeffrey Wolf, with its maturity extended to March 1, 2026.
• Settlement of a contingent earn-out receivable from Elusys Holdings, Inc. for $550,000, which was originally a $2.5 million obligation.
• Issuance of 2025 Non-Convertible Promissory Notes with an aggregate original issuance of $4,610,000 (and an additional $5,859,005 subsequent to June 30, 2025) to an institutional investor identified as a related party.
• Jeffrey Wolf provided a Personal Guaranty, dated May 16, 2025, by and between Jeffrey Wolf and 3i, L.P.
• The company entered into a twelve-month credit facility for up to $5.0 million with the holder of the 2025 Non-Convertible Promissory Notes, Related Party, on October 6, 2025.

Stakeholder Impact

• Shareholders face significant dilution if new equity is issued, potential loss of investment if the company liquidates or files for bankruptcy, and reduced liquidity/visibility due to delisting to OTC Markets Pink Limited.
• Creditors (holders of December 2024 Secured Convertible Notes and 2025 Non-Convertible Promissory Notes) have experienced defaults and had proceeds from asset sales applied to their debt, with significant amounts still outstanding.
• Employees are impacted by the cessation of operations, implying significant job losses or cessation of employment.
• Customers of the CDMO business have had contracts canceled, completed, or suspended indefinitely due to lack of funding, as the company no longer has CDMO operations.

Next Steps

• Seek a strategic transaction such as a reverse merger or asset acquisition.
• Raise additional capital to fund public company expenses and potential new ventures.
• Remediate identified material weaknesses in internal control over financial reporting.
• Potentially file for bankruptcy, liquidate, or reorganize if financing or strategic alternatives are unsuccessful.

Key Dates

Recommendation

The company has ceased all operations, sold its core assets, defaulted on substantial debt, and been delisted from a major exchange. It is now a "Shell Company" with critically low cash reserves, expected to last only through January 2026. Management has expressed substantial doubt about its ability to continue as a going concern and is exploring bankruptcy or liquidation as potential outcomes. There is no clear path to generating revenue or securing sufficient financing, making the stock highly speculative with a significant risk of total loss for investors.

Keywords

Scorpius Holdings, 10-Q, SEC filing, biomanufacturing, CDMO, shell company, going concern, delisting, debt default, liquidation, reverse merger, financial distress, OTC Markets, asset sale, quarterly report